Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 3

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 3
---

Miami, Florida 33131

(786) 432-9792

NOTICE OF SPECIAL MEETING OF STOCKHOLDERS

TO BE HELD ON , 2025

Dear Stockholder of MIRA:</div>

On behalf of the board of directors of MIRA Pharmaceuticals, Inc., a Florida corporation (“MIRA”), we are pleased to deliver this proxy statement for a virtual special meeting of stockholders of MIRA (the “MIRA virtual special meeting”), for the proposed merger between MIRA and SKNY Pharmaceuticals, Inc., a Delaware corporation (“SKNY”), pursuant to which MIRAPHARM Acquisition Inc., a Delaware corporation and wholly owned subsidiary of MIRA, will merge with and into SKNY, with SKNY surviving as a wholly owned subsidiary of MIRA (the “Merger”).

Notice is hereby given that the MIRA virtual special meeting will be held on , 2025, at Eastern Time. To facilitate stockholder participation in the MIRA virtual special meeting, we have determined that the MIRA virtual special meeting will be held in a virtual meeting format only, via the internet, with no physical in-person meeting. You will be able to attend and participate in the MIRA virtual special meeting online by visiting to register for the meeting, where you will be able to listen to the meeting live, submit questions, and vote. To participate, vote or submit questions during the MIRA virtual special meeting via live webcast, you must register in advance at prior to the meeting. Please note that you will not be able to attend the MIRA virtual special meeting in person. MIRA is holding the MIRA virtual special meeting to consider the following proposals:

| 1. | approve                                                                                            
 the issuance of shares of common stock of MIRA, $0.0001 par value per share (“MIRA                 
 Common Stock”), or other securities of MIRA pursuant to the Merger, which will represent           
 (or are convertible into) more than 20% of the shares of MIRA Common Stock outstanding immediately 
 prior to the Merger, pursuant to Nasdaq Listing Rule 5635(a) (the “Merger Proposal”                
 or “Proposal No. 1”); and                                                                          |

| 2. | approve                                                                                           
 a postponement or adjournment of the Merger virtual special meeting, if necessary, to solicit     
 additional proxies if there are not sufficient votes in favor of Proposal No. 1 (the “Adjournment 
 Proposal” or “Proposal No. 2